Next Generation Flow™ solution
for Plasma Cell Dyscrasias
Plasma Cell Screening Tube (PCST)
- An initial screening step based on a limited number of antibodies orientates efficiently to the need of further characterization of plasma cell dyscrasias (PCD) samples.
- Prognostic stratification based on the expression of the β2-microglobulin antigen.
- Suitable for evaluation of bone marrow samples.
Characterization of Plasma Cell Dyscrasias
Characterization panels comprise the use of core markers to consistently identify the population of study in all tubes and other markers for characterization and classification of the cells in a specific disease entity.
- The use of premixed combinations reduces operational mistakes, pipetting time and inventory management requirements. Just add the required single antibodies to complete the panel.
A strong technical support team with the scientific-based knowledge and practical experience to implement Next Generation Flow™
Cytognos Technical Support team have the required experience, know-how and training resources to achieve successful implementation of the NGF methodology independently of the site (public and private hospitals, research facilities or other). The following points are addressed during technical support:
- SOPs for cytometer set-up: Instrument standardization introduced in all labs.
- SOPs and stable lyophilized kits for sample processing: Inter and intra laboratory reproducibility.
- Data analysis: Reference databases with standardized reports bring a common language to the different sites.
Technical support is available through email, webinars or onsite visits. Cytognos provides a variety of solutions and products specifically aimed at the establishment of Next Generation Flow™ in your lab. Feel free to contact us to know more about them.
- Paiva B, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom. 2010 Jul;78(4):239-52. Go to publication.
- van Dongen JJ, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908-75. Go to publication.
- Flores-Montero J, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–103. Go to publication.
- Flores-Montero J, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. Go to publication.
- Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2016 Aug;17(8):e328-e346. Go to publication.
- Sanoja-Flores L, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on Circulating Tumor Plasma Cells (CTPC). Blood Cancer J. 2018;8(12):117. Go to publication.
- Sanoja-Flores L, et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019 Oct; 8(12):epub. Go to publication.